In the latest bid to widen access to medicines, a nonprofit is sending technology and materials for making expensive CAR-T cell therapies to the Brazilian government and an Indian manufacturer that will, in turn, look to provide the treatments available at a fraction of current prices in the U.S.
The deals will initially involve manufacturing cell therapies for combating lymphoma and leukemia, which carry price tags in the hundreds of thousands of dollars in wealthy nations. By offering its own equipment and expertise, though, the nonprofit, Caring Cross, believes governments and patients should be able to recognize substantial savings.
“We’re trying to crack this nut of affordability and accessibility,” Boro Dropulic, who heads Caring Cross, explained. “But we’re not offering the same products that are approved for elsewhere. These are not generic versions. There are no patents protecting anybody from making these. These are novel products, because we have the knowledge to make CAR-T therapies.”
Click this link for the original source of this article.
Author: Ed Silverman
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.